DNA vaccines: Focus on increasing potency and efficacy

International Journal of Pharmaceutical Medicine

Volumn 19, Issue 1, 2005, Pages 15-28

  Srivastava, Indresh K ^a   Singh, Manmohan ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALGINIC ACID; BACTERIAL VACCINE; CANCER VACCINE; CHITOSAN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; GAG PROTEIN; HOUSE DUST ALLERGEN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOSTIMULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LIPID; MICROSPHERE; PHOSPHORYL LIPID A; POLYETHYLENEIMINE; POLYGLACTIN; POVIDONE; PROTOZOAL VACCINE; QS 21; RECOMBINANT PROTEIN; UNINDEXED DRUG; VIRUS VACCINE;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; BACTERIAL INFECTION; BORRELIA INFECTION; BREAST CANCER; CELLULAR IMMUNITY; CLINICAL TRIAL; COLON CANCER; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DELTA AGENT HEPATITIS; DIABETES MELLITUS; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG TOLERABILITY; EPIDEMIC ENCEPHALITIS; EXPRESSION VECTOR; FIBROSARCOMA; GENE EXPRESSION; GENE GUN; GRAM NEGATIVE INFECTION; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HOUSE DUST ALLERGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOSTIMULATION; LEISHMANIASIS; LYMPHOMA; MALARIA; MEASLES; MYCOBACTERIOSIS; MYELOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PAPILLOMA; PEANUT ALLERGY; PRIORITY JOURNAL; PROSTATE CANCER; RABIES; RESPIRATORY TRACT ALLERGY; REVIEW; SCHISTOSOMIASIS; SLOW RELEASE FORMULATION; TOXOPLASMOSIS; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS ATTENUATION; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS MENINGITIS; VIRUS VECTOR;

EID: 33644530043     PISSN: 13649027     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124363-200519010-00004     Document Type: Review

References (210)

1. Donnelly JJ, Liu MA, Ulmer JB. Antigen presentation and DNA vaccines. Am J Respir Crit Care Med 2000; 162 (4 Pt 2): S190-3
2. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-8
3. Tang DC, De Vit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356 (6365): 152-4
4. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259 (5102): 1745-9
5. Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 1993; 90 (24): 11478-82
6. Wang B, Ugen KE, Srikantan V, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1993; 90 (9): 4156-60
7. Xiang ZQ, Spitalnik S, Tran M, et al. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 1994; 199 (1): 132-40
8. Davis HL, Michel ML, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet 1993: 2 (11): 1847-51
9. Shiver JW, Perry HC, Davies ME, et al. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination. Ann N Y Acad Sci 1995; 772: 198-208
10. Liu MA, Yasutomi Y, Davies ME, et al. Vaccination of mice and nonhuman primates using HIV-gene-containing DNA. Antibiot Chemother 1996; 48: 100-4
11. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292 (5514): 69-74
12. Cherpelis S, Srivastava I, Gettie A, et al. DNA vaccination with the human immunodeficiency virus type 1 SF162Delta V2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. J Virol 2001; 75 (3): 1547-50
13. Wang B, Boyer JD, Ugen KE, et al. Nucleic acid-based immunization against HIV-I; induction of protective in vivo immune responses. AIDS 1995; 9 Suppl. A: S159-70
14. Fuller DH, Simpson L, Cole KS, et al. Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Immunol Cell Biol 1997; 75 (4): 389-96
15. Haigwood NL, Pierce CC, Robertson MN, et al. Protection from pathogenic SIV challenge using multigenic DNA vaccines. Immunol Lett 1999; 66 (1-3): 183-8
16. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290 (5491): 486-92
17. Luke CJ, Carner K, Liang X, et al. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. J Infect Dis 1997; 175 (1): 91-7
18. Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282 (5388): 476-80
19. Sedegah M, Hedstrom R, Hobart P, et al. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A 1994; 91 (21): 9866-70
20. Hoffman SL, Sedegah M, Hedstrom RC. Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine. Vaccine 1994; 12 (16): 1529-33
21. Sedegah M, Jones TR, Kaur M, et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci U S A 1998; 95 (13): 7648-53
22. Sedegah M, Weiss W, Sacci JB, et al. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J Immunol 2000; 164 (11): 5905-12
23. Hoffman SL, Doolan DL, Sedegah M, et al. Toward clinical trials of DNA vaccines against malaria. Immunol Cell Biol 1997; 75 (4): 376-81
24. Doolan DL, Hedstrom RC, Gardner MJ, et al. DNA vaccination as an approach to malaria control: current status and strategies. Curr Top Microbiol Immunol 1998; 226: 37-56
25. Pilon SA, Piechocki MP, Wei WZ. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol 2001; 167 (6): 3201-6
26. Pupa SM, Invernizzi AM, Forti S, et al. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther 2001; 8 (1): 75-9
27. Lachman LB, Rao XM, Kremer RH, et al. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice. Cancer Gene Ther 2001; 8 (4): 259-68
28. von Herrath MG, Whitton JL. DNA vaccination to treat autoimmune diabetes. Ann Med 2000; 32 (5): 285-92
29. Prud'homme GJ, Chang Y, Li X. Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand. Hum Gene Ther 2002; 13 (3): 395-406
30. Yankauckas MA, Morrow JE, Parker SE, et al. Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. DNA Cell Biol 1993; 12 (9): 771-6
31. Webster RG, Fynan EF, Santoro JC, et al. Protection of ferrets against influenza challenge with a DNA vaccine to the hemagglutinin. Vaccine 1994; 12 (16): 1495-8
32. Donnelly JJ, Friedman A, Martinez D, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1995; 1 (6): 583-7
33. Stratford R, Douce G, Zhang-Barber L, et al. Influence of codon usage on the immunogenicity of a DNA vaccine against tetanus. Vaccine 2000; 19 (7-8): 810-5
34. Lai WC, Bennett M, Johnston SA, et al. Protection against Mycoplasma pulmonis infection by genetic vaccination. DNA Cell Biol 1995; 14 (7): 643-51
35. Xiang R, Primus FJ, Ruehlmann JM, et al. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol 2001; 167 (8): 4560-5
36. White SA, LoBuglio AF, Arani RB, et al. Induction of anti-tumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccine. J Gene Med 2000; 2 (2): 135-40
37. Roy K, Mao HQ, Huang SK, et al. Oral gene delivery with chitosan: DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5 (4): 387-91
38. Lobell A, Weissert R, Storch MK, et al. Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J Exp Med 1998; 187 (9): 1543-8
39. Kumar V, Maglione J, Thatte J, et al. Induction of a type 1 regulatory CD4 T cell response following V beta 8.2 DNA vaccination results in immune deviation and protection from experimental autoimmune encephalomyelitis. Int Immunol 2001; 13 (6): 835-41
40. Xiang ZQ, Spitalnik SL, Cheng J, et al. Immune responses to nucleic acid vaccines to rabies virus. Virology 1995; 209 (2): 569-79
41. Lodmell DL, Ray NB, Parnell MJ, et al. DNA immunization protects nonhuman primates against rabies virus. Nat Med 1998; 4 (8): 949-52
42. Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 2 (8): 893-8
43. Tascon RE, Colston MJ, Ragno S, et al. Vaccination against tuberculosis by DNA injection. Nat Med 1996; 2 (8): 888-92
44. Ulmer JB, Liu MA, Montgomery DL, et al. Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination. Vaccine 1997; 15: 792-4
45. Xu D, Liew FY. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of 1-major. Immunology 1995; 84 (2): 173-6
46. Kim JJ, Yang JS, Nottingham LK, et al. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen. Oncogene 2001; 20 (33): 4497-506
47. Hsu CH, Chua KY, Tao MH, et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1996; 2 (5): 540-4
48. Schirmbeck R, Bohm W, Ando K, et al. Nucleic-acid vaccination primes hepatitis-B virus surface antigen-specific cytotoxic T-lymphocytes in nonresponder mice. J Virol 1995; 69 (10): 5929-34
49. Kuhrober A, Wild J, Pudollek HP, et al. DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping Kb- and Kd-restricted epitopes. Int Immunol 1997; 9 (8): 1203-12
50. Major ME, Vitvitski L, Mink MA, et al. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol 1995; 69 (9): 5798-805
51. Lagging LM, Meyer K, Hoft D, et al. Immune-responses to plasmid DNA encoding the hepatitis-c virus core protein. J Virol 1995; 69 (9): 5859-63
52. Kuhober A, Pudollek HP, Reifenberg K, et al. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice. J Immunol 1996; 156 (10): 3687-95
53. Prince AM, Whalen R, Brotman B. Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine 1997; 15 (8): 916-9
54. Geissler M, Gesien A, Tokushige K, et al. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 1997; 158 (3): 1231-7
55. Roy MJ, Wu MS, Barr LJ, et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000; 19 (7-8): 764-78
56. Yang W, Waine GJ, Mcmanus DP. Antibodies to Schistosoma japonicum (Asian bloodfluke) paramyosin induced by nucleic acid vaccination. Biochem Biophys Res Commun 1995; 212 (3): 1029-39
57. King CA, Spellerberg MB, Zhu D, et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998; 4 (11): 1281-6
58. Xu L, Sanchez A, Yang Z, et al. Immunization for ebola virus infection. Nat Med 1998; 4 (1): 37-42
59. Angus CW, Klivington-Evans D, Dubey JP, et al. Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents. J Infect Dis 2000; 181 (1): 317-24
60. Vercammen M, Scorza T, Huygen K, et al. DNA vaccination with genes encoding Toxoplasma gondii antigens GRA1, GRA7, and ROP2 induces partially protective immunity against lethal challenge in mice. Infect Immun 2000; 68 (1): 38-45
61. Thirdborough SM, Radcliffe JN, Friedmann PS, et al. Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against t-cell lymphoma. Cancer Res 2002; 62 (6): 1757-60
62. Manickan E, Yu Z, Rouse RJ, et al. Induction of protective immunity against herpes simplex virus with DNA encoding the immediate early protein ICP 27. Viral Immunol 1995; 8 (2): 53-61
63. Manickan E, Rouse R, Yu ZY, et al. Genetic immunization against herpes-simplex-virus protection is mediated by CD4 (+) t-lymphocytes. J Immunol 1995; 155 (1): 259-65
64. Ghiasi H, Cai S, Slanina S, et al. Vaccination of mice with herpes-simplex virus type-1 glycoprotein-D DNA produces low-levels of protection against lethal HSV-1 challenge. Antiviral Res 1995; 28 (2): 147-57
65. McClements WL, Armstrong ME, Keys RD, et al. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci U S A 1996; 93 (21): 11414-20
66. Bourne N, Stanberry LR, Bernstein DI, et al. DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis 1996; 173 (4): 800-7
67. Bourne N, Milligan GN, Schleiss MR, et al. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine 1996; 14 (13): 1230-4
68. Paglia P, Medina E, Arioli I, et al. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 1998; 92 (9): 3172-6
69. Donnelly JJ, Martinez D, Jansen KU, et al. Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis 1996; 173 (2): 314-20
70. Sundaram P, Xiao W, Brandsma JL. Particle-mediated delivery of recombinant expression vectors to rabbit skin induces high-titered polyclonal antisera (and circumvents purification of a protein immunogen). Nucleic Acids Res 1996; 24 (7): 1375-7
71. Sundaram P, Tigelaar RE, Xiao W, et al. Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against virus challenge. Vaccine 1998; 16 (6): 613-23
72. Endresz V, Kari L, Berencsi K, et al. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine 1999; 17 (1): 50-8
73. Morello CS, Cranmer LD, Spector DH. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65). J Virol 2000; 74 (8): 3696-708
74. Herrmann JE, Chen SC, Fynan EF, et al. Protection against rotavirus infections by DNA vaccination. J Infect Dis 1996; 174 (1): 93-7
75. Herrmann J, Chen S, Fynan E, et al. DNA vaccines against rotavirus infections. Arch Virol Suppl 1996; 12: 207-15
76. Fooks AR, Jeevarajah D, Warnes A, et al. Immunization of mice with plasmid DNA expressing the measles virus nucleoprotein gene. Viral Immunol 1996; 9 (2): 65-71
77. Schlereth B, Germann PG, ter Meulen V, et al. DNA vaccination with both the haemagglutinin and fusion proteins but not the nucleocapsid protein protects against experimental measles virus infection. J Gen Virol 2000; 81 Pt 5 (10): 1321-5
78. Yokoyama M, Zhang J, Whitton JL. DNA immunization confers protection against lethal lymphocytic choriomeningitis virus-infection. J Virol 1995; 69 (4): 2684-8
79. Martins LP, Lau LL, Asano MS, et al. DNA vaccination against persistent viral infection. J Virol 1995; 69 (4): 2574-82
80. Chang GJ, Davis BS, Hunt AR, et al. Flavivirus DNA vaccines: current status and potential. Ann N Y Acad Sci 2001; 951: 272-85
81. Shiver JW, Davies ME, Yasutomi Y, et al. Anti-HIV env immunities elicited by nucleic acid vaccines. Vaccine 1997; 15 (8): 884-7
82. Boyer JD, Chattergoon M, Shah A, et al. HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTL response. Dev Biol Stand 1998; 95: 147-53
83. Thomson SA, Sherritt MA, Medveczky J, et al. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J Immunol 1998; 160 (4): 1717-23
84. Donnelly JJ, Ulmer JB, Liu MA. Protective efficacy of intramuscular immunization with naked DNA. Ann N Y Acad Sci 1995; 772: 40-6
85. Allen TM, Vogel TU, Fuller DH, et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 2000; 164 (9): 4968-78
86. Barouch DH, Craiu A, Santra S, et al. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J Virol 2001; 75 (5): 2462-7
87. Wang B, Boyer J, Srikantan V, et al. DNA inoculation induces neutralizing immune-responses against human-immunodeficiency-virus type-1 in mice and nonhuman-primates. DNA Cell Biol 1993; 12 (9): 799-805
88. Richmond JF, Lu S, Santoro JC, et al. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol 1998; 72 (11): 9092-100
89. Ourmanov I, Bilska M, Hirsch VM, et al. Recombinant modified vaccinia virus Ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques. J Virol 2000; 74 (6): 2960-5
90. Barnett SW, Lu S, Srivastava I, et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001; 75 (12): 5526-40
91. Mitchell WM, Rosenbloom ST, Gabriel J. Induction of mucosal anti-HIV antibodies by facilitated transfection of airway epithelium with lipospermine/DNA complexes. Immunotechnology 1995; 1 (3): 211-9
92. Sasaki S, Tsuji T, Asakura Y, et al. The search for a potent DNA vaccine against AIDS: the enhancement of immunogenicity by chemical and genetic adjuvants. Anticancer Res 1998; 18 (5D): 3907-15
93. Jones DH, Corris S, McDonald S, et al. Poly(DL-lactide-co-glycolide)- encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 1997; 15 (8): 814-7
94. Orson FM, Kinsey BM, Hua PJ, et al. Genetic immunization with lung-targeting macroaggregated polyethyleneimine-albumin conjugates elicits combined systemic and mucosal immune responses. J Immunol 2000; 164 (12): 6313-21
95. Mittal SK, Aggarwal N, Sailaja G, et al. Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine 2000; 19 (2-3): 253-63
96. Wang SW, Kozlowski PA, Schmelz G, et al. Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions. J Virol 2000; 74 (22): 10514-22
97. Manthorpe M, Cornefertjensen F, Hartikka J, et al. Gene-therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene-expression in mice. Hum Gene Ther 1993; 4 (4): 419-31
98. Haas J, Park EC, Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996; 6 (3): 315-24
99. zur Megede J, Chen MC, Doe B, et al. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J Virol 2000; 74 (6): 2628-35
100. Srivastava IK, Stamatatos L, Legg H, et al. Purification and characterization of oligomeric envelope glycoprotein from a primary r5 subtype B human immunodeficiency virus. J Virol 2002; 76 (6): 2835-47
101. Wu L, Barry MA. Fusion protein vectors to increase protein production and evaluate the immunogenicity of genetic vaccines. Mol Ther 2000; 2 (3): 288-97
102. Planelles L, Thomas MC, Alonso C, et al. DNA immunization with trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection. Infect Immun 2001; 69 (10): 6558-63
103. Tobery TW, Siliciano RF. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med 1997; 185 (5): 909-20
104. Rodriguez F, Zhang J, Whitton JL. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 1997; 71 (11): 8497-503
105. Deliyannis G, Boyle JS, Brady JL, et al. A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge. Proc Natl Acad Sci U S A 2000; 97 (12): 6676-80
106. Lew AM, Brady BJ, Boyle BJ. Site-directed immune responses in DNA vaccines encoding ligand-antigen fusions. Vaccine 2000; 18 (16): 1681-5
107. Drew DR, Boyle JS, Lew AM, et al. The comparative efficacy of CTLA-4 and L-selectin targeted DNA vaccines in mice and sheep. Vaccine 2001; 19 (31): 4417-28
108. You Z, Huang X, Hester J, et al. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res 2001; 61 (9): 3704-11
109. Biragyn A, Kwak LW. B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions. Immunol Rev 1999; 170: 115-26
110. Iwasaki A, Barber BH. Induction by DNA immunization of a protective antitumor cytotoxic T lymphocyte response against a minimal-epitope-expressing tumor. Cancer Immunol Immunother 1998; 45 (5): 273-9
111. Iwasaki A, Dela Cruz CS, Young AR, et al. Epitope-specific cytotoxic T lympho cyte induction by minigene DNA immunization. Vaccine 1999; 17 (15-16): 2081-8
112. Fomsgaard A, Nielsen HV, Kirkby N, et al. Induction of cytotoxic T-cell responses by gene gun DNA vaccination with minigenes encoding influenza A virus HA and NP CTL-epitopes. Vaccine 1999; 18 (7-8): 681-91
113. Hanke T, McMichael A. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol Lett 1999; 66 (1-3): 177-81
114. Livingston BD, Newman M, Crimi C, et al. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 2001; 19 (32): 4652-60
115. Leifert JA, Lindencrona JA, Charo J, et al. Enhancing T cell activation and antiviral protection by introducing the HIV-1 protein transduction domain into a DNA vaccine. Hum Gene Ther 2001; 12 (15): 1881-92
116. Dupuis M, Denis-Mize K, Woo C, et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000; 165 (5): 2850-8
117. Manam S, Ledwith BJ, Barnum AB, et al. Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 2000; 43 (4-6): 273-81
118. Aguiar JC, Hedstrom RC, Rogers WO, et al. Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine 2001; 20 (1-2): 275-80
119. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999; 6 (4): 508-14
120. Zucchelli S, Capone S, Fattori E, et al. Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol 2000; 74 (24): 11598-607
121. Selby M, Goldbeck C, Pertile T, et al. Enhancement of DNA vaccine potency by electroporation in vivo. J Biotechnol 2000; 83 (1-2): 147-52
122. Widera G, Austin M, Rabussay D, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000; 164 (9): 4635-40
123. Kircheis R, Wightman L, Wagner E. Design and gene delivery activity of modified polyethylenimines. Adv Drug Deliv Rev 2001; 53 (3): 341-58
124. Perez C, Sanchez A, Putnam D, et al. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release 2001; 75 (1-2): 211-24
125. Sato N, Kobayashi H, Saga T, et al. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin Cancer Res 2001; 7 (11): 3606-12
126. Rudolph C, Lausier J, Naundorf S, et al. In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers. J Gene Med 2000; 2 (4): 269-78
127. Ilium L, Jabbal-Gill I, Hinchcliffe M, et al. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001; 51 (1-3): 81-96
128. Singh M, Briones M, Ott G, et al. Cationic microparticles: a potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A 2000; 97 (2): 811-6
129. O'Hagan D, MacKichan M, Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 2001; 18: 69-85
130. Jones DH, Clegg JC, Farrar GH. Oral delivery of micro-encapsulated DNA vaccines. Dev Biol Stand 1998; 92: 149-55
131. Chen SC, Jones DH, Fynan EF, et al. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 1998; 72 (7): 5757-61
132. O'Hagan D, Singh M, Ugozzoli M, et al. Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines. J Virol 2001; 75 (19): 9037-43
133. Denis-Mize KS, Dupuis M, MacKichan ML, et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther 2000; 7 (24): 2105-12
134. Johnson RP. Live attenuated AIDS vaccines: hazards and hopes. Nat Med 1999; 5 (2): 154-5
135. Baba TW, Liska V, Khimani AH, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999; 5 (2): 194-203
136. Holzer GW, Remp G, Antoine G, et al. Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression. J Virol 1999; 73 (6): 4536-42
137. Belshe RB, Gorse GJ, Mulligan MJ, et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 1998; 12 (18): 2407-15
138. Adler SP, Plotkin SA, Gonczol E, et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 1999; 180 (3): 843-6
139. Evans TG, Keefer MC, Weinhold KJ, et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999; 180 (2): 290-8
140. Salmon-Ceron D, Excler JL, Finkielsztejn L, et al. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. AIDS Res Hum Retroviruses 1999; 15 (7): 633-45
141. Guirakhoo F, Zhang ZX, Chambers TJ, et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (Chimeri Vax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 1999; 257 (2): 363-72
142. Schnell MJ, Foley HD, Siler CA, et al. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A 2000; 97 (7): 3544-9
143. Xuan X, Tuchiya K, Sato I, et al. Biological and immunogenic properties of rabies virus glycoprotein expressed by canine herpesvirus vector. Vaccine 1998; 16 (9-10): 969-76
144. Callebaut P, Enjuanes L, Pensaert M. An adenovirus recombinant expressing the spike glycoprotein of porcine respiratory coronavirus is immunogenic in swine. J Gen Virol 1996; 77 (Pt 2): 309-13
145. Xiang ZQ, Pasquini S, Ertl HC. Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant. J Immunol 1999; 162 (11): 6716-23
146. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415 (6869): 331-5
147. Heineman TC, Connelly BL, Bourne N, et al. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol 1995; 69 (12): 8109-13
148. Mattion NM, Reilly PA, DiMichele SJ, et al. Attenuated poliovirus strain as alive vector: expression of regions of rotavirus outer capsid protein VP7 by using recombinant Sabin 3 viruses. J Virol 1994; 68 (6): 3925-33
149. Crotty S, Lohman BL, Lu FX, et al. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity. J Virol 1999; 73 (11): 9485-95
150. Davis NL, Caley IJ, Brown KW, et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol 2000; 74 (1): 371-8
151. Perri S, Driver DA, Gardner JP, et al. Replicon vectors derived from Sindbis virus and Semliki forest virus that establish persistent replication in host cells. J Virol 2000; 74 (20): 9802-7
152. Berglund P, Fleeton MN, Smerdou C, et al. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 1999; 17 (5): 497-507
153. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 1995; 270 (5234): 299-302
154. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization. Vaccine 1997; 15: 804-7
155. Xu F, Hong M, Ulmer JB. Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella. Vaccine 2003; 21 (7-8): 644-8
156. Dietrich G, Bubert A, Gentschev I, et al. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide listeria monocytogenes. Nat Biotechnol 1998; 16 (2): 181-5
157. Frankel FR, Hegde S, Lieberman J, et al. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using listeria monocytogenes as a live vaccine vector. J Immunol 1995; 155 (10): 4775-82
158. Soussi N, Milon G, Colle JH, et al. Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major. Infect Immun 2000; 68 (3): 1498-506
159. Darji A, Guzman CA, Gerstel B, et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 1997; 91 (6): 765-75
160. Jain V, Mekalanos JJ. Use of lambda phage S and R gene products in an inducible lysis system for Vibrio cholerae- and Salmonella enterica serovar typhimurium-based DNA vaccine delivery systems. Infect Immun 2000; 68 (2): 986-9
161. Tacket CO, Sztein MB, Wasserman SS, et al. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in US volunteers. Infect Immun 2000; 68 (3): 1196-201
162. Flo J, Tisminetzky S, Baralle F. Oral transgene vaccination mediated by attenuated Salmonellae is an effective method to prevent herpes simplex virus-2 induced disease in mice. Vaccine 2001; 19 (13-14): 1772-82
163. Sasaki S, Tsuji T, Asakura Y, et al. The search for a potent DNA vaccine against AIDS: the enhancement of immunogenicity by chemical and genetic adjuvants. Anticancer Res 1998; 18: 3907-16
164. Chow YH, Huang WL, Chi WK, et al. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol 1997; 71(1): 169-78
165. Barouch DH, Santra S, Steenbeke TD, et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 1998; 161 (4): 1875-82
166. Barouch DH, Letvin NL. DNA vaccination for HIV-1 and SIV. Intervirology 2000; 43 (4-6): 282-7
167. Kim JJ, Ayyavoo V, Bagarazzi ML, et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997; 158 (2): 816-26
168. Tsuji T, Hamajima K, Fukushima J, et al. Enhancement of cell-mediated immunity against HIV-1 induced by coinnoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immunol 1997; 158 (8): 4008-13
169. Maecker HT, Umetsu DT, Dekruyff RH, et al. DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin. Vaccine 1997 Oct; 15 (15): 1687-96
170. Chow YH, Chiang BL, Lee YL, et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998; 160 (3): 1320-9
171. Tuting T, Wilson CC, Martin DM, et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol 1998; 160 (3): 1139-47
172. Kim JJ, Trivedi NN, Nottingham LK, et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 1998; 28 (3): 1089-103
173. Raz E, Carson DA, Parker SE, et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A 1994; 91 (20): 9519-23
174. Morrissey PJ, Bressler L, Park LS, et al. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol 1987; 139 (4): 1113-9
175. Heufler C, Koch F, Schuler G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med 1988; 167 (2): 700-5
176. Kusakabe K, Xin KQ, Katoh H, et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 2000; 164 (6): 3102-11
177. Kim JJ, Yang JS, Dentchev T, et al. Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. J Interferon Cytokine Res 2000; 20 (5): 487-98
178. Okada E, Sasaki S, Ishii N, et al. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997; 159 (7): 3638-47
179. Iwasaki A, Stiernholm BJ, Chan AK, et al. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 1997; 158 (10): 4591-601
180. Sin JI, Sung JH, Suh YS, et al. Protective immunity against heterologous challenge with encephalomyocarditis virus by-VP1 DNA vaccination: effect of coinjection with a granulocyte-macrophage colony stimulating factor gene. Vaccine 1997; 15 (17-18): 1827-33
181. Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995; 2 (2): 129-35
182. Weiss WR, Ishii KJ, Hedstrom RC, et al. A plasmid encoding murine granulocytemacrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol 1998; 161 (5): 2325-32
183. Kim JJ, Bagarazzi ML, Trivedi N, et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol 1997; 15 (7): 641-6
184. Santra S, Barouch DH, Sharpe AH, et al. B7 co-stimulatory requirements differ for induction of immune responses by DNA, protein and recombinant pox virus vaccination. Eur J Immunol 2000; 30 (9): 2650-9
185. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374 (6522): 6546-9
186. Iho S, Yamamoto T, Takahashi T, et al. Oligodeoxynucleotides containing palindrome sequences with internal 5′-CpG-3′ act directly on human NK and activated T cells to induce IFN-gamma production in vitro. J Immunol 1999; 163 (7): 3642-52
187. Chuang TH, Lee J, Kline L, et al. Toll-like receptor 9 mediates CpG-DNA signaling. J Leukoc Biol 2002; 71 (3): 538-44
188. Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31 (10): 3026-37
189. Takeshita F, Leifer CA, Gursel I, et al. Cutting edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001; 167 (7): 3555-8
190. Hemmi H, Takeuchi O, Kawaii T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5
191. Sato Y, Roman M, Tighe H, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 273 (5273): 352-4
192. Elkins KL, Rhinehart-Jones TR, Stibitz S, et al. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol 1999; 162 (4): 2291-8
193. Donnelly JJ, Ulmer JB, Shiver JW, et al. DNA vaccines. Annu Rev Immunol 1997; 15: 617-48
194. Weeratna R, Brazolot Millan CL, Krieg AM, et al. Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev 1998; 8 (4): 351-6
195. Letvin NL, Montefiori DC, Yasutomi Y, et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A 1997; 94 (17): 9378-83
196. Schneider J, Gilbert SC, Blanchard TJ, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998; 4 (4): 397-402
197. Calarota SA, Kjerrstrom A, Islam KB, et al. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity. Hum Gene Ther 2001; 12 (13): 1623-37
198. MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178 (1): 92-100
199. MacGregor RR, Boyer JD, Ciccarelli RB, et al. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I Env/Rev vaccine in HIV-infected recipients: follow-up data. J Infect Dis 2000; 181 (1): 406
200. Calarota S, Bratt G, Nordlund S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351 (9112): 1320-5
201. Boyer JD, Cohen AD, Vogt S, et al. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J Infect Dis 2000; 181 (2): 476-83
202. MacGregor RR, Boyer JD, Ugen KE, et al. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8+ T-cell immunity and increased control of viral "blips". Vaccine 2005; 23: 2066-73
203. Le TP, Coonan KM, Hedstrom RC, et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000; 18 (18): 1893-901
204. McConkey SJ, Reece WH, Moorthy VS, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9 (6): 642-3
205. Wang R, Richie TL, Baraceros MF, et al. Boosting of DNA vaccine-elicited γ-interferon responses in humans by exposure to malaria parasites. Infect Immun 2005; 73: 2863-72
206. Webster DP, Dunachie S, Vuola JM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using recombinant pox viruses FP9 and modified vaccinia Ankara. Proc Natl Acad Sci U S A 2005; 102: 4836-41
207. Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282 (5388): 476-80
208. Stephenson J. Vaccine aimed at African HIV to begin trials [letter]. JAMA 2000; 284 (6): 683
209. Mwau M, Cebere I, Sutton J, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004; 85 (Pt 4): 911-9
210. Mancini-Bourgine M, Fontaine H, Scott-Algara D, et al. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004; 40 (4): 874-82